+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Circulating Tumor DNA"

From
From
Hemato Oncology Testing - Global Strategic Business Report - Product Thumbnail Image

Hemato Oncology Testing - Global Strategic Business Report

  • Report
  • April 2025
  • 92 Pages
  • Global
From
Oncology Biomarkers Market Report 2025 - Product Thumbnail Image

Oncology Biomarkers Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Cancer Biopsy Market Report 2024 - Product Thumbnail Image

Cancer Biopsy Market Report 2024

  • Report
  • December 2024
  • 175 Pages
  • Global
From
From
From
From
From
From
From
From
Loading Indicator

Circulating Tumor DNA (ctDNA) is a type of genetic material found in the bloodstream of cancer patients. It is a valuable tool for cancer diagnosis, prognosis, and treatment. ctDNA can be used to detect the presence of cancer, identify the type of cancer, and monitor the progression of the disease. It can also be used to detect mutations in cancer cells, which can help guide treatment decisions. ctDNA is a rapidly growing field in genomics, with many companies developing technologies to detect and analyze ctDNA. These companies are developing technologies such as next-generation sequencing, digital PCR, and microfluidics to detect and analyze ctDNA. Companies are also developing technologies to detect and analyze ctDNA in real-time, allowing for more accurate and timely diagnosis and treatment. Some companies in the ctDNA market include Illumina, Thermo Fisher Scientific, QIAGEN, Bio-Rad Laboratories, and Guardant Health. Show Less Read more